AntriaBio began engaging Prosciento to conduct a clinical study of AB101 for patients with diabetes mellitus.
AntriaBio (OTCQB:ANTB) entered a process to confirm if Prosciento will conduct a clinical study of AB101 for patients with diabetes mellitus.
As quoted in the press release:
AntriaBio plans to file an Investigational New Drug (IND) application for AB101 with the FDA in June 2017 and subsequently initiate a Phase 1 clinical study that will assess the safety, pharmacokinetics and pharmacology of sequential single doses of AB101 in subjects with type 1 diabetes mellitus.
“We are very excited to begin our first-in-human clinical study of once-weekly insulin and to have the opportunity to partner with Prosciento and leverage their extensive experience in conducting insulin pharmacology studies,” stated Brian Roberts, M.D., Vice President of Clinical Development at AntriaBio. “We look forward to generating clinical data that we believe will affirm the safety and long-acting pharmacology profile observed in preclinical proof of concept studies.”